Jeff Katstra - Galectin Therapeutics Head Development
| GALT Stock | USD 0.92 1.08 54.05% |
Executive
Jeff Katstra is Head Development of Galectin Therapeutics
| Address | 4960 Peachtree Industrial Boulevard, Norcross, GA, United States, 30071 |
| Phone | (678) 620-3186 |
| Web | https://galectintherapeutics.com |
Galectin Therapeutics Management Efficiency
The company has return on total asset (ROA) of (1.0387) % which means that it has lost $1.0387 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (37.2795) %, meaning that it created substantial loss on money invested by shareholders. Galectin Therapeutics' management efficiency ratios could be used to measure how well Galectin Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -1.53 in 2024. Return On Capital Employed is likely to gain to -2.89 in 2024. At this time, Galectin Therapeutics' Total Current Liabilities is comparatively stable compared to the past year. Non Current Liabilities Total is likely to gain to about 76.4 M in 2024, whereas Liabilities And Stockholders Equity is likely to drop slightly above 14.9 M in 2024.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| John Schembri | Akero Therapeutics | 62 | |
| Garth CPA | Inhibikase Therapeutics | 39 | |
| Jason Hoitt | Stoke Therapeutics | 46 | |
| CPA CPA | Viking Therapeutics | 53 | |
| PharmD MBA | Madrigal Pharmaceuticals | N/A | |
| Lorianne MD | DiaMedica Therapeutics | 63 | |
| Kim Fox | Milestone Pharmaceuticals | N/A | |
| Heba Nowyhed | Arcellx | N/A | |
| Jeffrey Nelson | Milestone Pharmaceuticals | 43 | |
| JD Esq | Terns Pharmaceuticals | 55 | |
| Linda Carter | PTC Therapeutics | N/A | |
| Christine Utter | PTC Therapeutics | 46 | |
| PMP PEng | Oncolytics Biotech | N/A | |
| Emil MD | Terns Pharmaceuticals | 44 | |
| Geoffrey Barker | Viking Therapeutics | N/A | |
| Mary Jenkins | Sarepta Therapeutics | N/A | |
| Edward Chiang | Madrigal Pharmaceuticals | N/A | |
| Patrick Mayo | Hepion Pharmaceuticals | N/A | |
| Diane Berry | Sarepta Therapeutics | N/A | |
| Roshan Girglani | Milestone Pharmaceuticals | N/A | |
| David Ege | Seres Therapeutics | 50 | |
Management Performance
| Return On Equity | -37.28 | ||||
| Return On Asset | -1.04 |
Galectin Therapeutics Leadership Team
Elected by the shareholders, the Galectin Therapeutics' board of directors comprises two types of representatives: Galectin Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Galectin. The board's role is to monitor Galectin Therapeutics' management team and ensure that shareholders' interests are well served. Galectin Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Galectin Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| CPA CPA, Treasurer CFO | ||
| Khurram MD, Chief Officer | ||
| Jack CPA, Treasurer CFO | ||
| Jeff Katstra, Head Development | ||
| Robert Tritt, General Counsel | ||
| Beth Knowles, Executive Manager | ||
| Joel Lewis, Independent Director |
Galectin Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Galectin Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -37.28 | ||||
| Return On Asset | -1.04 | ||||
| Current Valuation | 206.21 M | ||||
| Shares Outstanding | 62.76 M | ||||
| Shares Owned By Insiders | 30.95 % | ||||
| Shares Owned By Institutions | 15.77 % | ||||
| Number Of Shares Shorted | 5.86 M | ||||
| Price To Earning | (4.21) X | ||||
| Price To Book | 207.70 X | ||||
| EBITDA | (202 K) |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Galectin Stock Analysis
When running Galectin Therapeutics' price analysis, check to measure Galectin Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Galectin Therapeutics is operating at the current time. Most of Galectin Therapeutics' value examination focuses on studying past and present price action to predict the probability of Galectin Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Galectin Therapeutics' price. Additionally, you may evaluate how the addition of Galectin Therapeutics to your portfolios can decrease your overall portfolio volatility.